



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 11, 2014

Via Email

Kevin A. Pollack, Esq.
Chief Financial Officer
Lightlake Therapeutics Inc.
86 Gloucester Place, Ground Floor Suite
London, England W1U 6HP

**Re: Lightlake Therapeutics Inc.
Preliminary Proxy Statement on Schedule 14A
Filed August 8, 2014
File No. 333-139915**

Dear Mr. Pollack:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Brigitte Lippmann (for)

John Reynolds
Assistant Director

cc: Eric Stein, Esq.
Szaferman Lakind Blumstein & Blader, P.C.